AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25925019
Drug: Upper thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper thoracic manipulation (single session administered to the T1 vertebral area)
Trial: 29188387
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg b.i.d.
Trial: 12576428
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 or 600 mg/day)
Trial: 11314831
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (1 microg/kg), midazolam (0.05 to 0.075 mg/kg), and propofol (10 to 20 mg boluses as required)
Trial: 9173635
Drug: Community psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community psychiatric treatment
Trial: 9173635
Drug: Control district
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control district (no community psychiatric treatment)
Trial: 7892802
Drug: PREP for
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PREP for Effective Family Living Program (treatment group)
Trial: 3295380
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin treatment at a dose of 164.50 +/- 24.55 mg/kg body weight
Trial: 3295380
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin treatment at a dose of 359.65 +/- 58.62 mg/kg body weight
Trial: 3295380
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin treatment
Trial: 2285464
Drug: ORS‐90 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS‐90 (oral rehydration solution recommended by WHO)
Trial: 2285464
Drug: ORS‐60 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS‐60 (60 mmol/L sodium and 90 mmol/L glucose)
Trial: 16800
Drug: Antidepressant 1
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant 1
Trial: 16800
Drug: Antidepressant 2
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant 2
Trial: 16800
Drug: Antidepressant 3
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant 3
Trial: 16800
Drug: Antidepressant 4
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant 4
Trial: 16800
Drug: Antidepressant 5
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant 5
Trial: 16800
Drug: Antidepressant 6
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant 6
Trial: 27829521
Drug: Infants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants with preoperative serum chloride < 100mmol/L
Trial: 26077436
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 2% solution (40.4 mg/2 mL) BID for 7.5 days
Trial: 26077436
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 1.5% solution (19.3 mg/40 drops) QID for 7.5 days
Trial: 26077436
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac sodium 75 mg BID for 7.5 days
Trial: 23790158
Drug: Parent ratings
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent ratings of adolescents’ daily behaviors associated with executive functioning (EF)
Trial: 21860559
Drug: DA-9601 60
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-9601 60 mg three times daily
Trial: 21860559
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 µg three times daily
Trial: 17092740
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg oral dose
Trial: 8888028
Drug: Sodium ozagrel
RxNorm normalized name: Ozagrel
DrugBank: Ozagrel (DB12017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ozagrel (160 mg/day for two weeks)
Trial: 6220603
Drug: Moxalactam (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (250 mg every 12 hours)
Trial: 6220603
Drug: Tobramycin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1.0 mg/kg every eight hours)
Trial: 28869119
Drug: Home-based pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based pulmonary rehabilitation (3 sessions weekly for 8 weeks, aerobic exercise for 20min at 60-80% max stepping rate, resistance training with elastic band at 70% max voluntary isometric contraction)
Trial: 26375919
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise (CONCEX)
Trial: 23208878
Drug: New live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New live tetravalent dengue virus vaccine
Trial: 21810233
Drug: NEURAPAS® balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEURAPAS® balance (6 tablets)
Trial: 19371497
Drug: Lorazepam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (8 mg/day)
Trial: 19371497
Drug: Chlordiazepoxide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (80 mg/day)
Trial: 16413241
Drug: AVE7688 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE7688 25 mg
Trial: 16413241
Drug: AVE7688 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE7688 5 mg
Trial: 15571611
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder 1 g/day for 5 days
Trial: 15571611
Drug: Metoclopramide (oral)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (oral) for 4 days after placebo on the first day
Trial: 9339153
Drug: HVB suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVB suppositories
Trial: 9339153
Drug: PGB suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGB suppositories
Trial: 8232678
Drug: HELP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HELP treatment
Trial: 26694377
Drug: Continuous Erythropoietin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Erythropoietin Receptor Activator (CERA)
Trial: 8281355
Drug: Perennial immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perennial immunotherapy (602 BU cumulative dose)
Trial: 8281355
Drug: Seasonal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal immunotherapy (372 BU cumulative dose)
Trial: 28578704
Drug: Marine Phospholipids
RxNorm normalized name: marine phospholipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine Phospholipids (MPL) supplementation at 0.3 g of n-3-fatty acids per day for six weeks
Trial: 28578704
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish Oil (FO) supplementation at 0.3 g of n-3-fatty acids per day for six weeks
Trial: 16344336
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (75 mg hydroalcoholic gel applied daily)
Trial: 2189617
Drug: Quinapril (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (20, 40, 80 mg/day, once or twice daily)
Trial: 2189617
Drug: Quinapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10-40 mg/day, once or twice daily)
Trial: 2189617
Drug: Quinapril (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10, 20, and 40 mg/day, with optional titration)
Trial: 31151199
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil supplementation (400 mg EPA and DHA per day)
Trial: 31151199
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil supplementation (800 mg EPA + DHA per day)
Trial: 17183729
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose simvastatin (80 mg)
Trial: 10750576
Drug: Neridronate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (50 mg iv every 2 months for a year)
Trial: 9117754
Drug: 5% Amlexanox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Amlexanox oral paste
Trial: 8362449
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) once weekly
Trial: 8362449
Drug: Proguanil (PROG)
DrugBank: Proguanil (DB01131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proguanil (PROG) daily
Trial: 8362449
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chloroquine and Proguanil (CQ + PROG)
Trial: 3095780
Drug: Total antibiotic
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total antibiotic decontamination (TAD) with gentamicin, vancomycin and colimycin
Trial: 29492615
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral GR3027
Trial: 29492615
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg oral GR3027
Trial: 23035890
Drug: g-FOBT (guaiac-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: g-FOBT (guaiac-based fecal occult blood test)
Trial: 18552672
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard microsurgical treatment)
Trial: 8769206
Drug: Neoral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral therapy
Trial: 1385658
Drug: Graded activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded activity program with a behavioral therapy approach (n = 51)
Trial: 30272245
Drug: Active V1
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active V1 subcutaneous trigeminal nerve stimulation (sTNS) as adjuvant to medical therapy
Trial: 20096909
Drug: Praneem polyherbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praneem polyherbal tablet
Trial: 12476932
Drug: Prednisolone, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 20 mg twice daily
Trial: 10330639
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of 0.5 mL lidocaine 1%
Trial: 8955574
Drug: Injective immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injective immunotherapy
Trial: 1836290
Drug: 10 mcg
RxNorm normalized name: D400, 10 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mcg recombinant DNA yeast-derived hepatitis B vaccine
Trial: 1836290
Drug: 20 mcg
RxNorm normalized name: Caverject 20 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg recombinant DNA yeast-derived hepatitis B vaccine
Trial: 1836290
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (10 mcg and 20 mcg)
Trial: 7425396
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (11 patients receiving injections for the first time)
Trial: 7425396
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (20 patients already receiving injections)
Trial: 7425396
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (20 control patients who did not receive any injections)
Trial: 31274231
Drug: E39 +
RxNorm normalized name: E39' vaccine
DrugBank: GALE-302 (DB17962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E39 + GM-CSF vaccine (1000 μg)
Trial: 31274231
Drug: E39 +
RxNorm normalized name: E39' vaccine
DrugBank: GALE-302 (DB17962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E39 + GM-CSF vaccine (<1000 μg)
Trial: 31274231
Drug: E39 +
RxNorm normalized name: E39' vaccine
DrugBank: GALE-302 (DB17962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E39 + GM-CSF vaccine (any dose)
Trial: 28696286
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin treatment (24 International Units, twice daily for 4 weeks)
Trial: 25282519
Drug: Placebo monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo monthly
Trial: 2660519
Drug: Muroctasin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muroctasin (both doses)
Trial: 29077862
Drug: ASP requiring
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP requiring re-authorization of restricted antibiotics on day 3
Trial: 26747333
Drug: 24,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24,000 IU of vitamin D3 plus 300 μg of calcifediol
Trial: 26415294
Drug: Kruarone 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kruarone 0.6 mg/kg
Trial: 20920765
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg) + Budesonide (200 μg)
Trial: 20920765
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 μg)
Trial: 17015817
Drug: Ramelteon (16,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (16, 80, or 160 mg)
Trial: 17015817
Drug: Triazolam (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25, 0.5, or 0.75 mg)
Trial: 12821462
Drug: Gemifloxacin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin administered alone
Trial: 12821462
Drug: Gemifloxacin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin administered simultaneously with calcium carbonate
Trial: 12821462
Drug: Gemifloxacin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin administered 2 h before calcium carbonate
Trial: 12821462
Drug: Gemifloxacin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin administered 2 h after calcium carbonate
Trial: 10804490
Drug: Placement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of a subcutaneous closed suction drain
Trial: 31518454
Drug: Triangular neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triangular neck implant (test)
Trial: 31518454
Drug: Round neck
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round neck implant (control)
Trial: 31518454
Drug: Both implants
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implants (triangular and round neck)
Trial: 31518454
Drug: Triangular neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triangular neck implant
Trial: 24587355
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg AMP at encoding and placebo at retrieval (condition AP)
Trial: 2234715
Drug: Elective delivery
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective delivery 48 hours after administration of betamethasone (aggressive-management group)
Trial: 736293
Drug: Atropine, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine, 0.4 mg
Trial: 736293
Drug: Glycopyrrolate, 0.2
RxNorm normalized name: Glycopyrrolate, 0.2 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate, 0.2 mg
Trial: 736293
Drug: Saline solution,
RxNorm normalized name: Sterile Saline Solution, Contact Lens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution, 1 ml
Trial: 736293
Drug: No anticholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticholinergic drug
Trial: 24067488
Drug: Nurse-led algorithm-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led algorithm-based treatment
Trial: 24067488
Drug: Gastroenterologist-led algorithm-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastroenterologist-led algorithm-based treatment
Trial: 21424588
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula (5 L/min)
Trial: 21424588
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask (5 L/min)
Trial: 18344727
Drug: Venlafaxine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine monotherapy
Trial: 18344727
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate monotherapy
Trial: 15607840
Drug: Illicit use
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit use of prescription pain medication from peers
Trial: 15607840
Drug: Illicit use
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit use of prescription pain medication from family members
Trial: 15607840
Drug: Previous prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous prescription of pain medication
Trial: 840556
Drug: Daily phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily phenobarbital
Trial: 26123286
Drug: Ferric(III)carboxymaltose infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric(III)carboxymaltose infusion
Trial: 26123286
Drug: Ferrofumarate (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrofumarate (oral iron supplementation)
Trial: 21457153
Drug: Subcostal TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcostal TAP catheters with 1 mg.kg(‐1) bupivacaine 0.375% every 8 h
Trial: 21457153
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine 0.125% and fentanyl 2 μg.ml(‐1)
Trial: 19318435
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of large waist circumference and elevated glucose
Trial: 11912568
Drug: Topiramate (512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (512 mg/day)
Trial: 8163132
Drug: Second-look endoscopy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-look endoscopy within the first 24 hours with repeated injection if a visible vessel was still identified
Trial: 20458988
Drug: Frozen gel
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen gel pack applied to sternal incision dressing before DB & C exercises
Trial: 20458988
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel pack
Trial: 11549104
Drug: Theophylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (600 mg) alone
Trial: 11549104
Drug: Tegaserod (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (6 mg) and Theophylline (600 mg)
Trial: 11549104
Drug: Tegaserod (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (6 mg)
Trial: 9928569
Drug: Infusional 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusional 5-FU 200 mg/m2 per day for up to 6 months in combination with 3-weekly bolus epirubicin (60 mg/m2) and cisplatin (60 mg/m2)
Trial: 30431605
Drug: Modified quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified quadruple therapy (proton‐pump inhibitor bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily)
Trial: 30431605
Drug: Bismuth‐containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth‐containing quadruple therapy (proton‐pump inhibitor bid, tetracycline 500 mg qid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily)
Trial: 25305762
Drug: 25‐µg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐µg sublingual misoprostol with vaginal placebo
Trial: 25305762
Drug: 50‐µg intravaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50‐µg intravaginal misoprostol with sublingual placebo